4D pharma to Participate in Jefferies London Healthcare Conference

Rhea-AI Summary

4D pharma plc (NASDAQ: LBPS) announces management participation in the Jefferies London Virtual Healthcare Conference on November 18-19, 2021. The company is a leader in developing Live Biotherapeutics, biological products derived from the microbiome, and is recognized for its proprietary platform, MicroRx®. Currently, it has five clinical programs, including a Phase I/II study of MRx0518 combined with KEYTRUDA for solid tumors and a completed Phase II trial of Blautix® for IBS. Additionally, 4D pharma collaborates with MSD for vaccine development.

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D pharma management will participate in the Jefferies London Virtual Healthcare Conference, being held November 18-19, 2021.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005291/en/

4D pharma

Investor Relations: ir@4dpharmaplc.com

Singer Capital Markets - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

neil@ibcomms.agency / michelle@ibcomms.agency

Source: 4D pharma plc

FAQ

What is the significance of 4D pharma participating in the Jefferies London Virtual Healthcare Conference?

4D pharma's participation in the conference highlights its commitment to advancing its innovative Live Biotherapeutics and connecting with investors and healthcare professionals.

What are Live Biotherapeutics and how are they developed by 4D pharma?

Live Biotherapeutics are biological products containing live organisms aimed at treating diseases. 4D pharma uses its MicroRx® platform to identify and develop these therapies.

What clinical programs are currently being developed by 4D pharma?

4D pharma has five clinical programs, including studies for MRx0518 in solid tumors and asthma, as well as Blautix® for Irritable Bowel Syndrome, which has completed Phase II trials.

What collaboration does 4D pharma have with MSD?

4D pharma collaborates with MSD to discover and develop Live Biotherapeutics for vaccines, indicating a strategic partnership in advancing therapeutic innovations.

When are the dates for the Jefferies London Virtual Healthcare Conference?

The Jefferies London Virtual Healthcare Conference will take place on November 18-19, 2021.